Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
118 hedge funds and large institutions have $605M invested in Accelerate Diagnostics in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 46 increasing their positions, 23 reducing their positions, and 18 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 23
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
1% less funds holding
Funds holding: 119 → 118 (-1)
11% less capital invested
Capital invested by funds: $683M → $605M (-$78.2M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
62% less call options, than puts
Call options by funds: $5.69M | Put options by funds: $15.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$23M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
+$5.72M |
| 3 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$5.48M |
| 4 |
William Blair & Company
Chicago,
Illinois
|
+$3.93M |
| 5 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$3.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$7.62M |
| 2 |
MGM
Miura Global Management
New York
|
-$5.89M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$3.27M |
| 4 |
TCM
Timpani Capital Management
Milwaukee,
Wisconsin
|
-$2.53M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.32M |
AXDX Hedge Fund Activity: Q3 2017 in Review
118 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q3 2017, worth a combined $605M — down 11% from $683M a quarter earlier.
Fund positioning in AXDX was balanced in Q3 2017: 18 funds opened new positions, 18 closed out, 46 added to existing stakes and 23 trimmed.
The largest buyer was Credit Suisse, adding an estimated $23M. The largest seller was Russell Investments Group, exiting entirely with an estimated $7.62M sold.
- 118 institutional investors held Accelerate Diagnostics (AXDX) as of Q3 2017, down from 119 in Q2 2017.
- Funds reported $605M of Accelerate Diagnostics stock for Q3 2017, down 11% quarter-over-quarter.
- 18 funds opened new Accelerate Diagnostics positions in Q3 2017 and 18 closed out, a net change of 0 holders.
- The largest Accelerate Diagnostics buyer in Q3 2017 was Credit Suisse, an estimated $23M added.
- The largest Accelerate Diagnostics seller in Q3 2017 was Russell Investments Group, an estimated $7.62M sold.
Based on aggregated 13F filings for Q3 2017.